Levi & Korsinsky, LLP announces that it has commenced an investigation
of Neos Therapeutics, Inc. (“Neos Therapeutics” or the “Company”)
(NASDAQGM:NEOS) concerning possible violations of federal securities
laws by the Company and/or certain of its officers and directors.
On October 19, 2015, Neos Therapeutics disclosed that the U.S. Food and
Drug Administration has identified deficiencies in the Company’s new
drug application for Cotempla XR-ODT that preclude discussion of
labeling and marketing requirements at this time. Shares of Neos
Therapeutics were down more than 23% on intraday trading on October 20,
2015. To obtain additional information about the investigation, go to:
http://zlk.9nl.com/neos-therapeutics-neos
or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com
or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York, New
Jersey, Connecticut and Washington D.C. The firm’s attorneys have
extensive expertise in prosecuting securities litigation involving
financial fraud, representing investors throughout the nation in
securities and shareholder lawsuits. Attorney advertising. Prior results
do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30
Broad Street - 24th Floor
New York, NY 10004
Tel: (212)
363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20151020006319/en/
Copyright Business Wire 2015